Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Mar 18, 2008
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biocryst Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
|
Mar 14
| |||||||
Biocryst Pharmaceuticals Inc
|
0
|
$9.18 | -$112,890.75 |
—
| 65.73K |
Sep 4
|
Scheduled
| ||||||
Biocryst Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
|
May 16
| |||||||
Biocryst Pharmaceuticals Inc
| 16.17K |
$5.89 | $95,277.72 | +32.63% | 65.73K |
Feb 26
| |||||||
Biocryst Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
|
Jun 22
| |||||||
Biocryst Pharmaceuticals Inc
| 6.56K |
$6.50 | $42,659.50 | +15.26% | 49.56K |
May 10
| |||||||
Biocryst Pharmaceuticals Inc
| 8.76K |
$10.82 | -$169,633.59 | +25.58% | 43K |
May 3
| |||||||
Biocryst Pharmaceuticals Inc
| 684 |
$17.20 | -$5,298.18 | +2.04% | 34.24K |
Apr 3
|
Scheduled
| ||||||
Biocryst Pharmaceuticals Inc
| 1.55K |
$18.69 | -$20,841.81 | +4.84% | 33.55K |
Mar 3
|
Scheduled
| ||||||
Biocryst Pharmaceuticals Inc
| 3.17K |
$11.70 | -$10,956.47 | +10.98% | 32.01K |
Feb 13
| |||||||
Biocryst Pharmaceuticals Inc
| 3.8K |
$3.59 | $13,642.00 | +19.52% | 23.27K |
Jul 13
| |||||||
Biocryst Pharmaceuticals Inc
| 9.37K |
$2.05 | $19,180.70 | +48.12% | 28.84K |
Jul 13
| |||||||
Biocryst Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
|
May 11
| |||||||
Biocryst Pharmaceuticals Inc
| 2.72K |
$1.60 | $4,347.55 | +16.23% | 19.47K |
Feb 7
| |||||||
Biocryst Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
|
May 12
| |||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||